Research and Clinical Trials

Title  
Pharmacyclics PCYC-1123-CA: A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton?s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Ly
Brief Description  
To evaluate the efficacy of ibrutinib in combination with lenalidomide with or without rituximab by assessing the overall response in subjects with relapsed or refractory non-GCB DLBCL.
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Non-Hodgkin's Lymphoma
Status  
OPEN
Start Date  
11/22/2016
IRB Number  
00009411
Principal Investigator  
Ghosh, Nilanjan
Contact Name  
Leslie Walker

For More Information, Contact  Leslie  , Walker
Phone:  980-442-2033 Fax:    
Email:  Leslie.Walker@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204
Close